-
公开(公告)号：US20220169594A1
公开(公告)日：2022-06-02
申请号：US17398408
申请日：2021-08-10
申请人： Orphalan S.A.
IPC分类号： C07C211/14 , C07C209/84
摘要： The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
-
公开(公告)号：US10947184B2
公开(公告)日：2021-03-16
申请号：US16917266
申请日：2020-06-30
申请人： ORPHALAN S.A.
IPC分类号： C07C211/14 , C07C209/84 , A61K9/00
摘要： The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
-
公开(公告)号：US20210163398A1
公开(公告)日：2021-06-03
申请号：US17171347
申请日：2021-02-09
申请人： Orphalan S.A.
IPC分类号： C07C211/14 , C07C209/84
摘要： The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
-
公开(公告)号：US11072577B2
公开(公告)日：2021-07-27
申请号：US17171358
申请日：2021-02-09
申请人： Orphalan S.A.
IPC分类号： C07C211/14 , C07C209/84 , A61K9/00
摘要： The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
-
公开(公告)号：US20210188761A1
公开(公告)日：2021-06-24
申请号：US17171358
申请日：2021-02-09
申请人： Orphalan S.A.
IPC分类号： C07C211/14 , C07C209/84
摘要： The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
-
6.发明公开公开(公告)号：US20240360071A1
公开(公告)日：2024-10-31
申请号：US18386906
申请日：2023-11-03
申请人： Orphalan S.A.
IPC分类号： C07C211/14 , A61K9/00 , C07C209/84
CPC分类号： C07C211/14 , C07C209/84 , A61K9/0053 , C07B2200/13
摘要： The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
-
公开(公告)号：US11117855B2
公开(公告)日：2021-09-14
申请号：US17171347
申请日：2021-02-09
申请人： Orphalan S.A.
IPC分类号： C07C211/14 , C07C209/84 , A61K9/00
摘要： The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
-
公开(公告)号：US10988436B2
公开(公告)日：2021-04-27
申请号：US16917266
申请日：2020-06-30
申请人： ORPHALAN S.A.
IPC分类号： C07C211/14 , C07C209/84 , A61K9/00
摘要： The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.014 秒)
